Apart from the abovementioned translational approaches, FGF10 expression (both at the gene and protein levels) needs to be better clinically characterized within the heterogeneous cohort of preterm infants at risk of developing BPD-PH (e.g., gestation age, risk factors for BPD-PH, postnatal ventilation regimes, and genetic predisposition). This evidence concerns the gene FGF10 and bronchopulmonary dysplasia.